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2ABSTRACT 
Our study aimed to target adenoviral gene therapy to the utero-placental circulation of pregnant 
guinea pigs in order to develop a novel therapy for fetal growth restriction. Four methods of 
delivery of an adenovirus encoding β-galactosidase (Ad.LacZ) were evaluated: intravascular 
injection using phosphate buffered saline (PBS) into (1) uterine artery or (2) internal iliac artery, 
or external administration in (3) PBS or (4) Pluronic F-127 gel (Sigma Aldrich).  Post mortem 
examination was performed 4-7 days after gene transfer. Tissue transduction was assessed by X-
gal histochemistry and ELISA. External vascular application of the adenovirus vector in 
combination with pluronic gel had 91.7% success rate in terms of administration (85% maternal 
survival) and gave the best results for maternal/fetal survival and local transduction efficiency 
without any spread to maternal or fetal tissues. This study suggests an optimal method of gene 
delivery to the uterine arteries of a small rodent for pre-clinical studies. 
3Introduction 
Fetal Growth Restriction (FGR) is an obstetric complication in which the fetus does not achieve 
its genetically determined growth potential. Pregnancies complicated by FGR have an increased 
rate of perinatal complications and mortality, and long term there is an increased risk of 
cardiovascular and neurological disorders1-6. It has been established that reduced uteroplacental 
perfusion can cause FGR and to the best of our knowledge, treatments or management strategies 
remain elusive. 
We have previously shown that in pregnant sheep, there was a significant increase in uterine 
blood flow (UBF) for up to one month after injection of adenovirus vectors containing the VEGF-
A165 gene when compared with uterine arteries (UtAs) injected with a control adenovirus 
containing the -galactosidase gene7,8. Moreover, we have demonstrated a reduction in UtA 
contractility and adventitial neovascularization 30-45 days after local administration of 
Ad.VEGF-A165 to the UtAs of pregnant sheep7,8. There was no undesirable vector expression in 
other maternal/fetal tissues as determined by semi-nested RT-PCR. Recent data from sheep 
pregnancies affected by fetal growth restriction demonstrates that mid-gestation maternal UtA 
injection of Ad.VEGF-A165 vector led to fewer instances of marked FGR, defined as fetal weight 
more than two standard deviations from the contemporaneous non growth restricted control 
mean, at term9.  There was also a fall in ratio of the head (biparietal diameter, BPD) to abdominal 
size (abdominal circumference, AC) over gestation, which was significantly lower at term than 
control untreated FGR fetuses, and no different to non growth restricted control fetuses. There 
was no significant difference in the BPD measurements, suggesting that the “brain sparing” that 
is seen in this paradigm of fetal growth restriction had been ameliorated9.
The guinea pig is an appropriate model for human FGR and normal pregnancy as compared with 
other rodents, since their placentation is more similar to that of human; having a homologous 
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haemochorial type of placenta, as in humans12. Interventions such as periconceptual maternal 
nutrient restriction leads to asymmetric growth restriction with similar long term consequences to 
human FGR13. The long gestational age of 65-68 days in the guinea pig allows time for therapy to 
be administered in mid or late gestation and for an effect on fetal growth to be realized.   
Therapeutic adenoviral vector delivery to adult guinea pigs has been described via the following 
injection routes: intradermal14, subcutaneous15, intramuscular16, intraarticular17, heart (left 
ventricle)18 and intracochlear19. Senoo et al. detected the adenovirus vector in several fetal organs, 
after injecting vectors into the umbilical vein of late gestation guinea pig fetuses at laparotomy20; 
our aim however was to test different methods to achieve localized maternal gene delivery to the 
uterine arteries without spread to the fetus as a therapeutic approach to prevent FGR. We propose 
that maternal gene therapy localized to the uterine vasculature, producing an increase in 
uteroplacental perfusion, represents a solution to treating FGR, and this is currently being 
translated into the clinic in the EVERREST programme (www.everrest-fp7.eu). Our long term 
goal is to first evaluate if local maternal VEGF gene transfer to the uterine and radial arteries 
improves fetal growth in an FGR guinea pig model, and later in human pregnancies complicated 
by FGR. For this purpose, the experiments described were conducted with an adenovirus 
encoding a reporter gene β-galactosidase rather than VEGF, in order to be able to quickly stain 
the blood vessels and evaluate the extent of transgenic protein over-expression. We tested two 
local uteroplacental intravascular routes of administration and an external vascular transduction 
method combining vector with either PBS or pluronic gel. Pluronic gel is a thermolabile gel that 
is liquid when cold, but solidifies at body temperature. It has commonly been used for drug and 
viral delivery to a variety of vascular beds in pre-clinical and clinical studies and shown to be safe 
to administer, non-irritant and cytocompatible21-24.  
5Methods 
Time-mated female Dunkin Hartley guinea pigs (Harlan Animal Research Laboratory, UK) were 
scanned at 20-30 days gestational age (dga) to confirm pregnancy, using a 7-10 MHz probe 
(Siemens, Bracknell, United Kingdom). A midline laparotomy was performed under general 
anaesthesia (diazepam 5mg/kg, atropine 0.5mg/kg, ketamine 40 mg/kg; Hameln Pharmaceuticals, 
Gloucester, UK) at either ~30 dga or ~45 dga, maintained by isoflurane inhalation (1.5-2.0%) and 
an adenovirus vector encoding for a reporter β-galactosidase gene (Ad.LacZ, 1x1010 viral 
particles per animal) was administered to the uterine and radial arteries by four different methods 
described below.  
Intra-vascular injection of the vector into the uterine arteries 
For direct injection into uterine arteries, the vessel (200-350 μm diameter) was located as it ran in 
the posterior surface of the mesometrium lying parallel and lateral to each uterine horn, and 
visualised using a light (KL 1500 LCD, Schott, Mainz, Germany) shone through the 
mesometrium from behind. A 3cm section of the uterine artery within the posterior surface of the 
mesometrium was gently cleared of surrounding fat and exposed using a small straight vannas 
scissors (103102, John Weiss and Company, Milton Keynes, UK). The vessel proximal to the 
injection site was temporarily occluded using a microvascular clip (610195, Harvard Apparatus, 
Kent, UK) and the vector (1x1010 viral particles of Ad.LacZ in a volume of 0.5-1.3 ml PBS) was 
then administered over approximately 1 minute using a custom made 34 Gauge needle mounted 
on a short 5cm catheter attached to a 1ml syringe. Once the needle was removed, a second 
microvascular clip was placed over the injection site to compress the injection site, for a 
minimum of 3 minutes after which both occluders were removed and the vessel was carefully 
observed for bleeding. If necessary to achieve haemostasis, adrenaline (10μl, Hameln 
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procedure was then attempted in the uterine artery on the other horn. 
Intra-vascular injection of the vector into the internal iliac arteries 
The internal iliac artery has the uterine artery as its most distal branch situated approximately 
3.5cm from the origin of the internal iliac artery (Figure 1). For direct injection of the internal 
iliac artery, the vessel was identified as it runs with a neurovascular bundle along the pelvic side 
wall beneath the posterior aspect of the peritoneum at the level of the cervix. Careful dissection of 
the parietal peritoneum over the neurovascular bundle with a small straight vannas scissors 
revealed the prominent internal iliac vein, and the smaller sized artery (200 – 250 μm in diameter) 
behind it, as it coursed transversely from its origin at the common iliac artery towards the cervical 
parametrium. A 1.5cm portion of the artery was exposed, and the vessel was temporarily 
occluded using a microvascular clip, and the vector was administered distal to the occlusion over 
approximately 1 minute using a 34 Gauge needle as described before (1x1010 viral particles in 
1.0-1.5 ml of PBS). Following vector injection and removal of the needle, a second micro-
vascular clip was placed over the injection site for 3 minutes. Both clips were then removed and 
the vessel was carefully observed for bleeding. Adrenaline was applied externally to the vessel if 
necessary, as described before, to achieve haemostasis.  The injection procedure was then 
attempted on the opposite side internal iliac artery. 
A successful injection of the uterine or internal iliac arteries was defined as the vector fluid seen 
moving down the vessel during injection. Failed injections were due to vector being inadvertently 
injected into the vessel wall, leaking out of the vessel or coming out of the other side of the 
vessel, opposite the injection site. In case of failed injections, 1-2 further attempts to inject the 
artery were made. A dissecting microscope (Discovery V8 Stereomicroscope, Carl Zeiss Ltd., 
Herts UK) was used to visualise vessels during dissection and intravascular injection. 
7External administration of the vector to the uterine arteries in PBS 
For external vascular administration of the vector in PBS, the vector (1x1010 viral particles 
Ad.LacZ in a total volume of 0.5-1.0 ml PBS bilaterally) was dribbled onto the exposed uterine 
artery within the mesometrial fat and the vessel was left still for 5 minutes before the uterus was 
subsequently mobilized. Previous experiments in sheep have demonstrated that a 5 minute 
contact period of the vector with the uterine artery is sufficient to result in significant transgenic 
protein expression7.  During this 5 minute time period, if access to the uterine artery necessitated 
the uterus to be lifted out of the abdominal cavity, the uterine horn was kept warm and moist by 
wrapping it in a sterile gauze soaked with warm saline. No vessel occlusion was used in this 
technique. For radial artery gene transfer, the uterine horn on one side was moved across to 
expose the arteries as they ran within the uterine mesometrium. Sometimes it was not possible to 
transduce the uterine artery and radials at the same time because of difficulties in exposing all 
these vessels simultaneously. In such instances, the uterine artery was transduced first and after a 
5 minute wait, the radials were exposed and transduced. The procedure was repeated on the 
contralateral side.  
External administration of the vector to the uterine arteries in pluronic gel 
For external vascular administration of the vector in Pluronic gel, the vector was combined with a 
freshly made thermo-sensitive polymer gel (Pluronic F-127) that is liquid when cold, but 
gelatinizes when brought to room temperature. A 25% (w/v) solution of Pluronic F-127 (P2443, 
Sigma Aldrich, USA) was prepared by dissolving the powder in cold double distilled de-ionized 
water the day before surgery. The solution was placed on a rotating platform overnight at 4°C to 
ensure the polymer was homogenously mixed. Immediately before administration, the vector 
(Ad.LacZ, 1x1010 viral particles) was reconstituted in 1 ml of Pluronic gel and mixed by gently 
pipetting up and down, on ice. After exposing the uterine artery as it ran within the mesometrium, 
8the vector-pluronic gel combination was dribbled onto the external surface of the uterine artery 
using a 1ml micro-pipette, and left to solidify for 5 minutes. Similarly the radial arteries were 
then transduced for a further 5 minutes. No vessel occlusion was used in this technique. The 
procedure was then repeated on the contralateral side.  
After vector administration (by either of the four methods described above), the abdomen was 
closed in layers. The rectus sheath was closed with continuous 2-0 Vicryl with Tapercut needle 
(Ethicon, St. Stevens-Woluwe, Belgium) to prevent herniation of the abdominal contents. The 
subcutaneous tissue and skin were closed with continuous 2-0 Vicryl with Tapercut needle 
(Ethicon, St. Stevens-Woluwe, Belgium) and continuous 2-0 Vicryl with Cutting needle (Ethicon, 
St. Stevens-Woluwe, Belgium) respectively. A 10% solution of lidocaine hydrochloride (0.5ml) 
was administered subcutaneously just before closing the skin to provide local anaesthesia. 
Because there are only few antibiotics that are well-tolerated in guinea pigs, and many of those 
commonly used ones such as Penicillin-streptomycin kill their symbiotic gut flora, no antibiotics 
were administered intra-peritoneally prior to closing the incision. Following surgeries and 
recovery, animals were monitored for signs of miscarriage.  
Post-mortem examination 
Scheduled post-mortem examination was performed 4-7 days after the administration of the 
vector, unless necessitated earlier by miscarriage or maternal distress. Survival data is presented 
on each route of injection. All procedures on animals were conducted in accordance with UK 
Home Office regulations and the Guidance for the Operation of Animals (Scientific Procedures 
Act 1986). 
The fetuses were carefully evaluated for signs of miscarriage. Widespread sampling of maternal 
and fetal tissues was performed (maternal organs including uterine and radial arteries, uterus, 
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adrenal, spleen and gonad). A detailed post mortem examination and microbiological culture of 
tissues was performed on tissues of animals that died after surgery to determine the cause of 
death. 
Transgenic protein expression 
For X-gal histochemistry tissue samples were placed in 100% ethanol at post-mortem 
examination and fixed for at least 2 hours before washing with PBS. Samples were then incubated 
in X-gal staining solution overnight in a rotary shaker protected from light, as  described earlier7. 
Stained samples were then washed in PBS and photographed with a camera attached to a 
microscope (Discovery V8 Stereomicroscope, Carl Zeiss Ltd., Herts UK and Canon Powershot 
A620 digital camera).  
Enzyme-Linked Immuno Sorbent Assay (ELISA) 
β-galactosidase levels in the UtAs, radial arteries, placentae, uterus, maternal and fetal liver, 
heart, kidney, brain, spleen and gonads were determined by ELISA using a commercially 
available assay kit (Boehringer Mannheim, Mannheim, Germany) as previously described7. 
Statistics 
Results are presented as means±SEM. Statistical analysis was performed using GraphPad Prism 
Version 5 by using one-way ANOVA (Kruskal-Wallis Test), to compare β-galactosidase levels 
observed using the four different routes of administration. 
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Results   
The success rate of the four different methods of administration of adenoviral vectors to the 
uterine and radial arteries of pregnant guinea pigs is shown in Table 1.  Maternal survival was 
described in terms of survival to scheduled post mortem examination 4-7 days after surgery. 
1. Uterine artery injections 
Injection of the uterine arteries of pregnant guinea-pigs at 30 dga was hampered by technical 
difficulties due to the small size of the vessels at mid-gestation (150-250μm) preventing reliable 
and safe injection (n=2 out of 8; 25% success rate, 50% survival). Deferring injection until ¾ 
through gestation (45dga) was more feasible with successful injection seen in 44% of attempts (7 
out of 16 uterine arteries, n=8 dams), even though the vessels were still small (300-400μm 
diameter). The low success rate is attributed to difficulties dissecting out and injecting the uterine 
artery, which is deeply embedded in fat and is unsupported by the surrounding tissue. In addition 
it is likely that even in those apparently successfully injected vessels, much of the vector leaked 
out of the vessel and behaved similarly to the external administration of vector with PBS leading 
to poor local gene transfer. There were two maternal deaths, one during surgery that was ascribed 
to the long anaesthetic time (>4 hrs) and one within 24 hours of the surgery that was due to 
sepsis. There was no fetal loss in mothers who survived the procedure. 
Uterine artery injection (500μl vector) resulted in gene transfer to the cervical end of the uterine 
arteries and the cervical end radial arteries. Increasing the injected vector volume from 0.5ml to 
1.0ml resulted in gene transfer also to the radial arteries supplying the middle fetus (of three on 
one side).  However, even the maximum volume that was injected (1.3 ml) was not successful in 
transducing the ovarian end of the uterine artery and radial arteries supplying the fetus at the 
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ovarian end of the uterine horns. The maternal liver, uterus and placentae were marginally 
stained. No staining of the fetuses or placentae was seen.  
2) Injection of internal iliac arteries 
Internal iliac artery injection was successful in all 12 vessels (n=6 dams, 45-47 dga) although 
multiple attempts were required in each of the 12 vessels. Maternal survival was 66% (4 out of 6), 
fetal survival was 100% in those dams that survived. The deaths occurred only in the dams that 
received 1.5ml vector, which was probably related to bleeding following the multiple (5-6) 
attempts that were needed on each side to inject the full volume of vector, rather than vector 
toxicity.  
Administration of Ad.LacZ into the internal iliac artery resulted in positive X-gal staining in the 
internal iliac artery, maternal liver, pelvic muscles, bladder and cervix. There was no expression 
in the uterine/radial arteries, the fat around the uterine arteries, the placentae or fetuses. 
Increasing the volume of vector injected did not lead to positive expression in the uterine artery.  
3) External transduction of uterine and radial arteries with vector in PBS
External transduction of the exposed uterine artery by the vector in PBS was technically easy to 
perform, less traumatic compared with the intravascular injection methods with a good survival 
rate (5 out of 6 dams survived, no fetal losses in surviving dams).  The only maternal death 
happened during a long 4 hour surgery where exposure of the uterine artery was technically 
difficult and led to bleeding.  
External administration of the vector to the uterine and radial arteries resulted not only in positive 
expression in all the vessels on which the vector had been applied, but also in the fat surrounding 
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the uterine arteries. All radial arteries stained positively, as well as the maternal liver and uterus. 
Although there was slight staining in the placentae, there was none detected in the fetuses. 
4) External Administration of Vector-Pluronic Gel Combination
Administration of the vector in combination with thermolabile pluronic gel was technically 
straightforward, shortening the duration of the surgery by more than half (from 3-4 hours to only 
1 hour) with successful gene transfer in 91.7% of cases (n=11 out of 12 vessels, n=6 dams). Fetal 
survival was 100% in the dams that survived successfully. In one case it was not possible to 
administer the vector to the right uterine artery because the vessel was very small and 
consequently difficult to visualize within the fat pad. This dam miscarried the next morning, 
probably due to excessive manipulation of the uterine horn, which had to be exposed for long 
periods of time during surgery. There was no evidence of peritoneal inflammation, bleeding or 
infection at postmortem examination.  
Administration of Ad.LacZ using Pluronic gel as a vehicle led to very high levels of local 
transgenic protein expression in the uterine and radial arteries to which the vector had been 
applied, not only on the external surface but inner luminal surface as well. The liver and uterus 
had minimal β-galactosidase expression in one animal and did not stain positively in any of the 
other animals, when incubated in the X-gal staining solution overnight. All other maternal and 
fetal tissues sampled (placentae, heart, kidney, lung, gonad, bladder, brain and adrenal) did not 
show any positive staining with the X-gal staining solution.. Representative pictures of X-gal 
staining in the uterine arteries, after the different methods of administration, are shown in Figure 
2.  
Measurment of β–galactosidase levels by ELISA 
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Quantitative analysis of β–galactosidase expression in tissues using ELISA found that the most 
effective route of administration was combination of pluronic gel and vector, yielding the highest 
mean levels in samples collected from uterine artery (p=0.0048, n=4 vessels for each route of 
administration, one-way ANOVA). Administration of Ad.LacZ via uterine artery injection 
yielded similar results to external route of administration using PBS and Ad.LacZ vector 
combination. After internal iliac artery injection, no β–galactosidase expression was detected in 
uterine or radial arteries (Table 2, Figure 3).  
β-galactosidase expression was also quantified in the fetal tissues (kidney, gonad, muscle, bone 
marrow, thymus and amniotic fluid). The highest β-galactosidase concentration was observed in 
amniotic fluid (45 pg/mg) after administering vector externally to the uterine artery and radial 
arteries in PBS. The second highest value of β-galactosidase was observed in bone marrow (14 
pg/mg) after uterine artery injection with the vector. Placental β-galactosidase expression was 
detected only in the animals wherein external transduction  of Ad.LacZ was performed using PBS 
as a vehicle, and was quantified to be 57 pg/mg. None of the other tissues showed positive β-
galactosidase expression by any of the routes of administration.  
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Discussion
In this study we have demonstrated that the most effective method of gene transfer to the 
pregnant guinea pig uterine and radial arteries is external administration of the vector in 
combination with pluronic gel as a vehicle. Moreover, application of the vector by this technique 
is technically straightforward and atraumatic as an intravascular injection is not required. The 
delivery method achieved localized gene transfer restricted only to the uterine and radial arteries, 
with no spread of vector to other maternal and fetal tissues. Since pluronic gel becomes solid 
immediately after administration, due to its characteristic property of reversible thermogelation, 
there is minimal spread of the vector to other organs. In particular with relevance to maternal 
uteroplacental gene transfer, external vector administration using pluronic gel was safe for the 
developing fetus as there was no vector spread to fetal tissues. In addition external application of 
adenovirus either in pluronic gel or PBS achieved 84%-100% fetal survival, in contrast to direct 
intraplacental adenoviral administration, that only achieved fetal survival rates of 30%-42%25.  
Our results indicate that using a localized pluronic gel based depot of slow viral vector release 
facilitates greater transgene expression in comparison to other techniques, when direct vascular 
injection may be technically challenging. Pluronic gel has been used to deliver Ad.LacZ to the 
carotid artery of rats. Five days post-infection, the presence of the β-gal transgene was visualized 
throughout the arterial wall21. The combination of vector with pluronic gel has been used as a 
vehicle for virus-mediated gene delivery for a number of indications, but not previously to the 
vessels of the utero-placental circulation. Poloxamer gels display low toxicity at therapeutically 
beneficial doses and do not increase serum triglycerides and cholesterol in animal models26. 
Clinical uses of pluronic F-127 have included the controlled delivery of drugs to the eye27, nasal 
passage as well as parenteral and subcutaneous administration28. Pluronic gels have been used as 
a vehicle for local adenoviral gene delivery previously in pre-clinical and clinical studies21,23,29
and shown to be safe to administer. Depending on the concentration of the gel, it may last from a 
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few hours to a few days, undergoing slow dissolution in the body fluid.  Pluronics have been 
shown to be non-irritant, non-inflammatory and cytocompatible with many different cell types30. 
They are primarily cleared from the body via the renal route in the form of unimers31. They 
increase the transduction efficiency of adenoviral vector delivery to vascular cells in vivo 
compared to PBS24, probably because of the slower kinetics associated with the longer term 
vector release from the gel or the closer proximity of viral vector to the cell surface. Because of 
the thermo-responsive behaviour of pluronic F-127, the gel is delivered in vivo over a short period 
of time before solidification.  
In our study, a higher concentration of β-galactosidase expression was observed in the radial 
arteries compared with the uterine arteries. This might be due to the finding that the uterine 
arteries are deeply embedded in fat, whilst the radial arteries are only covered by a thin 
mesentery, allowing more effective diffusion of the viral vector through the vessel wall. External 
administration of Ad.LacZ vector combined with PBS led to low transgenic protein expression in 
the vessels, probably due to the low viscosity of PBS solution, which allowed it to spread from 
the target vessel to surrounding tissues. Although the uterine and radial arteries were left still for 
5 minutes after application of the PBS Ad.LacZ vector combination, the fluid was seen to dribble 
down into the pelvic cavity. Our previous work in sheep demonstrates that contact of the vector 
with the uterine artery for 5 minutes is sufficient to result in significant transgenic protein 
expression7. 
Intra-arterial administration of vector into the uterine arteries of pregnant guinea pigs only led to 
partial transduction of the utero-placental circulation that was limited to those vessels closest to 
the injection site. Increasing the volume of vector injected did not result in transduction of the 
furthest zones. Similarly, in an angiographic study to examine the vascular anatomy of guinea pig 
uterine arteries, contrast medium injected into the uterine artery in vivo failed to enter the most 
distal radial arteries and placentae32, probably because they are preferentially served by the 
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ovarian arteries. Vector injection into the ovarian arteries was considered, but because they were 
of even smaller diameter than the uterine arteries it was not attempted. Delivery into the uterine 
artery using interventional radiology was considered, since guinea pig uterine arteries have a 
sufficiently wide calibre at mid-gestation to be easily injectable by angiographic guided 
catheter25. We were concerned however that trauma to the vessel internally would result in a high 
rate of miscarriage. 
Although injection of internal iliac artery was feasible, gene transfer to the uterine arteries was 
not achieved and instead, there was gene transfer observed preferentially to the guinea-pig pelvis. 
This was not unexpected since the arteries supplying the pelvic musculature and organs are the 
first three branches of the internal iliac artery, which suggests that the vector has been redirected 
to those vessels by haemodynamic forces. Moreover, the technique was associated with 
significant fetal and maternal loss, most probably because of the long anaesthetic time required to 
complete the procedure.  
We observed that intra-vascular administration of Ad.LacZ as well as external administration in 
PBS resulted in strong liver transduction. Previous studies of adenovirus gene transfer in the 
guinea pig found a strong liver tropism, most likely due to the high density of coxsackievirus and 
adenovirus receptor on hepatocytes 33-36. We did not observe this liver tropism in dams which 
received Ad.LacZ in pluronic gel, most probably because the gel confined the viral particles to 
the site of administration with minimal spread to other tissues and organs.  
The efficacy of maternal uteroplacental VEGF gene therapy to treat FGR has been tested in 
growth restricted sheep where the large vessel size permits safe direct intravascular injection9. It 
was important for translation into the clinic to demonstrate efficacy for improved fetal growth in 
a second animal model of FGR, and we have chosen to use the guinea pig for reasons described 
previously. Safe and high level local gene transfer was not achieved using direct intravascular 
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injection due to the technical difficulties encountered, but was demonstrated using external 
administration with pluronic gel. Current studies are investigating the efficacy of this treatment in 
the maternal nutrient restricted guinea pig that has asymmetrical FGR, and will include 
examination of the mechanism of action of the intervention. For human trials, we propose using 
an interventional radiology technique to deliver vector into the uterine artery that is currently 
applied in the clinic for embolization of uterine fibroids37 or prevention of postpartum 
haemorrhage38. 
Direct adenovirus vector injection into the uterine arteries of pregnant sheep is safe and leads to 
high local transgenic protein expression with minimal maternal and fetal mortality or morbidity7-
9,39. Injection of the uterine artery in the rabbit can be achieved using catheter-mediated injection 
under angiographic control40. This leads to high transduction efficiency in the uterine artery and 
placental trophoplastic cells. The much smaller diameter of the guinea pig UtA compared to the 
sheep UtA makes its injections more challenging and more prone to complications.  
In summary, we have shown in the pregnant guinea pig that administration of recombinant 
adenoviruses using thermolabile pluronic gel as a vehicle leads to robust transgenic protein 
expression in the utero-placental vessels, both on the adventitial and luminal surfaces. There is no 
vector expression in other maternal and fetal tissues. Surgery time was shorter when compared to 
alternative intravascular injection methods, thereby lowering the risk of morbidity and mortality. 
Our findings suggest that vector administration using Pluronic F-127 as a vehicle is the optimum 
method of gene targeting to the uteroplacental blood vessels of pregnant guinea pigs.  
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Figure Legends 
Figure 1 - Diagram of the internal iliac artery and its branches in the guinea pig - cranial 
gluteal (supply the dorsolateral wall of pelvis), internal pudendal artery (supplying the external 
genitalia), inferior vesical artery (supplying the lower bladder and also forming the middle 
rectal artery supplying the rectum), vaginal artery and uterine artery, which is quite some way 
along the internal iliac artery. The injection sites on the uterine and internal iliac arteries have 
been marked.  
Figure 2 – X-gal staining of guinea pig uterine and radial arteries 4-7 days after Ad.LacZ 
administration by one of the following different routes (A) direct injection into the uterine artery; 
(B) external administration in PBS; (C) external administration in pluronic gel – uterine artery; 
(D) external administration in pluronic gel – radial artery; (E) external administration in pluronic 
gel – uterine artery (luminal/inside view). Even though direct injection into the uterine artery led 
to some expression of β-galactosidase, it was less than that achieved via external administration 
of the vector. Maximum local tissue transduction was achieved when Ad.LacZ was administered 
using pluronic gel as a vehicle. Scale bar = 150μm 
Figure 3 – Quantification of protein levels of β-galactosidase by ELISA in the uterine and radial 
arteries following the different routes of administration.  



Table 1 – Surgical parameters using the different gene delivery techniques. Ad.LacZ 
was administered to the uterine and radial arteries of pregnant guinea pigs at 40-45 
days of gestation, by one of the methods described in the table. The outcome of the 
surgery (in terms of maternal survival to scheduled post mortem examination 4-7 days 
after surgery) and the number of injection attempts required are summarised below.  
Method of Ad.LacZ vector 
administration 
Maternal 
Survival 
Time taken to 
inject 
Total number of 
injection attempts 
required (average) 
Uterine artery injection 6/8 
(75%) 
2-2.5 hrs 4 
Internal iliac injection 4/6 
(66%) 
2-2.5 hrs 5 
External administration in 
PBS 
5/6 
(83.3%) 
< 1 hr 1 
External administration in 
pluronic gel 
5/6 
(83.3%) 
< 1 hr 1 
Table 2 – Efficiency of gene transfer after administration of the vector using different routes. Tissue samples were collected at post-mortem examination and stained overnight in X-gal staining solution. Photomicrographs of the stained samples were carefully examined by a single observer who was blinded to the route of administration. The degree of blue staining, if any, was compared amongst all stained images and denoted as ‘+’ indicating least staining and ‘++++’ denoting maximum staining.  
Method of 
administration
Efficiency of gene transfer 
Uterine 
artery 
Radial 
artery 
Mat. Liver Mat. Lung Uterus Placenta 
Uterine artery 
injection 
++ - +++ - + - 
Internal iliac 
injection 
- - +++ - - - 
External 
administration in 
PBS 
++ +++ +++ - ++ + 
External 
administration in 
pluronic gel 
++++ ++++ - - - - 
